佰仁医疗(688198.SH)：2025年度营收同比增长25.60%

Core Viewpoint - The company, Baijun Medical (688198.SH), reported a strong performance for the fiscal year 2025, demonstrating resilience in its product lines amid industry policy changes and competitive pressures, achieving a revenue of 630.372 million yuan, a year-on-year increase of 25.60% [1] Financial Performance - The structural heart disease segment grew by 26.07% year-on-year, while the soft tissue repair segment increased by 24.23% [1] - The net profit attributable to the parent company reached 200.1903 million yuan, reflecting a year-on-year growth of 36.81% [1] - After excluding the impact of share-based payments, the net profit margin attributable to the parent company was 30.69%, aligning with the company's expectations [1]